Journal of Lipid Research · 2015 · 33 citations · 47 references
Life SciencesBiochemistryPharmacologyLipid BiochemistryMetabolic RegulationMolecular PharmacologyCholesterol BiosynthesisCholesterol MetabolismLipid MetabolismLipid-lowering TherapyLipoprotein MetabolismTriglyceride MetabolismHigh-density Lipoprotein MetabolismLdl Cholesterol LoweringLipoprotein Metabolism RegulationLow-density Lipoprotein Cholesterol ReductionPharmacological Inhibition Of Cholesterol BiosynthesisSterol Regulatory Element-binding Protein RegulationSterol Regulatory Element-binding ProteinsTriglyceride-rich Lipoproteins
Recently, we showed in APOE*3-Leiden cholesteryl ester transfer protein (E3L.CETP) mice that anacetrapib attenuated atherosclerosis development by reducing (V)LDL cholesterol [(V)LDL-C] rather than by raising HDL cholesterol. Here, we investigated the mechanism by which anacetrapib reduces (V)LDL-C and whether this effect was dependent on the inhibition of CETP. E3L.CETP mice were fed a Western-type diet alone or supplemented with anacetrapib (30 mg/kg body weight per day). Microarray analyses of livers revealed downregulation of the cholesterol biosynthesis pathway (P < 0.001) and predicted downregulation of pathways controlled by sterol regulatory element-binding proteins 1 and 2 (z-scores -2.56 and -2.90, respectively; both P < 0.001). These data suggest increased supply of cholesterol to the liver. We found that hepatic proprotein convertase subtilisin/kexin type 9 (Pcsk9) expression was decreased (-28%, P < 0.01), accompanied by decreased plasma PCSK9 levels (-47%, P < 0.001) and increased hepatic LDL receptor (LDLr) content (+64%, P < 0.01). Consistent with this, anacetrapib increased the clearance and hepatic uptake (+25%, P < 0.001) of [(14)C]cholesteryl oleate-labeled VLDL-mimicking particles. In E3L mice that do not express CETP, anacetrapib still decreased (V)LDL-C and plasma PCSK9 levels, indicating that these effects were independent of CETP inhibition. We conclude that anacetrapib reduces (V)LDL-C by two mechanisms: 1) inhibition of CETP activity, resulting in remodeled VLDL particles that are more susceptible to hepatic uptake; and 2) a CETP-independent reduction of plasma PCSK9 levels that has the potential to increase LDLr-mediated hepatic remnant clearance.
47
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Cardiology, Pharmacology +14
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
<i>lumi</i>: a pipeline for processing Illumina microarray
Pan Du, Warren A. Kibbe, Simon Lin · Bioinformatics · 2008 · 2.1K citations · Full text
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · New England Journal of Medicine · 2012 · 2K citations · Full text
Medicine, Cardiology, Pharmacology +17